Affiliate Disclosure: Aura Protocols earns commissions from qualifying purchases via affiliate links. This does not affect our editorial independence.
Growth & PerformanceMarch 20266 min read

CJC-1295 / Ipamorelin Stack: Growth Hormone Optimization

Why this combo has become the gold standard for GH-axis support in research settings.

Among growth hormone secretagogue combinations, CJC-1295 paired with Ipamorelin has emerged as one of the most researched and consistently cited stacks. The synergy between these two compounds — one a GHRH analogue, the other a selective ghrelin mimetic — produces robust, pulsatile GH release with a favorable safety profile compared to exogenous GH administration.

Understanding Each Compound

CJC-1295 (with DAC)

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) modification extends its half-life from minutes to approximately 6–8 days by binding to serum albumin. This produces sustained elevation of baseline GH and IGF-1 levels rather than sharp pulses.

Ipamorelin

Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist (GHSR). It is notable for its high selectivity — it stimulates GH release without significantly elevating cortisol or prolactin, which distinguishes it from older GH secretagogues like GHRP-2 and GHRP-6.

Why the Combination Works

CJC-1295 and Ipamorelin act on two distinct receptors within the GH axis — GHRH receptors and ghrelin receptors respectively. When combined, they produce a synergistic amplification of GH pulse amplitude. Research suggests the combination produces GH release 2–10x greater than either compound alone, while maintaining the physiological pulsatile pattern that exogenous GH disrupts.

  • CJC-1295 raises the baseline 'floor' of GH secretion
  • Ipamorelin amplifies individual GH pulses
  • Combined effect: higher amplitude pulses on an elevated baseline
  • Preserves natural GH rhythm unlike exogenous HGH
  • No significant cortisol or prolactin elevation (Ipamorelin selective)

Studied Effects

  • Increased lean body mass in multiple animal models
  • Reduction in adipose tissue, particularly visceral fat
  • Improved sleep quality (GH is primarily secreted during slow-wave sleep)
  • Enhanced recovery from exercise-induced muscle damage
  • Improved bone mineral density markers in aging models

CJC-1295 and Ipamorelin are research compounds only. They have not been approved by the FDA for human use. All referenced effects are from preclinical studies.

Recommended Vendor

Limitless Life Nootropics

View CJC-1295 / Ipamorelin at Limitless Life Nootropics

This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.